Brind.

GIMOTI, an FDA-approved nasal spray, is seeing expanded patient access through Omnicell and strategic support from EVERSANA.

1 report, 1 independent Updated Aug 26
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

GIMOTI, an FDA-approved nasal spray, is seeing expanded patient access through Omnicell and strategic support from EVERSANA.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • GlobeNewswireEvoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell Relationship Separately Secures Access to OneGI Through Brentwood Pharmacy Agreement Gim